Objective
Seventy-six million people will suffer from blindness by 2020. Age-related retinal disorders - macular degeneration (AMD) and diabetic macular edema (DME) are two of the leading causes of blindness in the world. About 200,000 new cases of advanced, age-related AMD identified each year in the United States and between 14.9 and 21.5 million cases of early AMD, and between 3.9 and 4.8 million cases of late AMD is expected in Europe by 2040. The complexity of eye anatomy presents challenges for treatment. Current treatment, intravitreal injections (IVI) are the highest growth medical procedure in the globe, with an estimated 20 million intravitreal injections globally in 2016. Ranibizumab, treatment blocking vascular endothelial growth factor (VEGF), which promotes blood vessel growth, costs approximately $2,000 in USA and €1000 per injection. Patients may need up to 12 injection per year. Additionally, this treatment significantly affects patient comfort.
MicroSert has developed BlueDot – a novel, long-acting release (LAR) ocular implant for the sustained delivery of biologics and small molecules for the treatment of retinal diseases. BlueDot is implantable to the tear duct and releases therapeutic inside the eye. Implantation requires one-step office-based procedure using proprietary implantation device with safety monitoring system and with no incision needed. BlueDot is refillable and lasts up to two years.
The SME-I Phase 1 project perfectly suits the innovation’s current stage of development and overall business strategy allowing MicroSert to check final specifications of BlueDot, establish a sound business development and gain partners necessary for the Phase II study.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine anatomy and morphology
- medical and health sciences clinical medicine ophthalmology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
3684224 NESHER
Israel
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.